材料科学
聚酯纤维
弹性体
热塑性弹性体
聚对苯二甲酸丁二醇酯
共聚物
热塑性塑料
药物输送
3D打印
聚合物
生物相容性材料
乙二醇
聚醚醚酮
复合材料
纳米技术
高分子科学
生物医学工程
化学工程
偷看
工程类
医学
作者
Ioannis Koutsamanis,Amrit Paudel,Carolina Patricia Alva Zúñiga,Laura Wiltschko,Martin Spoerk
标识
DOI:10.1016/j.jconrel.2021.05.030
摘要
To improve patient compliance and personalised drug delivery, long-acting drug delivery devices (LADDDs), such as implants and inserts, greatly benefit from a customisation in their shape through the emerging 3D-printing technology, since their production usually follows a one-size-fits-most approach. The use of 3D-printing for LADDDs, however, is mainly limited by the shortage of flawlessly 3D-printable, yet biocompatible materials. The present study tackles this issue by introducing a novel, non-biodegradable material, namely a polyester-based thermoplastic elastomer (TPC) – a multi-block copolymer containing alternating semi-crystalline polybutylene terephthalate hard segments and poly-ether-terephthalate amorphous soft segments. Next to a detailed description of the material's 3D-printability by mechanical, rheological and thermal analyses, which was found to be superior to that of conventional polymers (ethylene-vinyl acetates (EVA)), this study establishes the fundamental understandings of the interactions between progesterone (P4) and TPC and drug-releasing properties of TPC for the first time. P4-loaded LADDDs based on TPC, prepared via an elaborated solvent-immersion technique, enable the release of P4 at pharmacologically relevant rates, similar to those of marketed formulations based on EVA and silicones. Additionally, TPC demonstrated an exceptional 3D-printability for a wide selection of implant sizes and complex geometries.
科研通智能强力驱动
Strongly Powered by AbleSci AI